Genprex Inc — Cash Flow (NASDAQ:GNPX)

Financials

Cash from operating activities -13.94 M-14.28 M-17.78 M-24.74 M-17.15 M-15.31 M -15.31 M Cash from investing activities -2.34 M-83.8 K97.73 K-71.21 K1 1660 0 Cash from financing activities 41.59 M25.68 M6 42610.59 M12.01 M21.54 M 21.54 M Free cash flow -14.06 M-14.36 M-17.84 M-24.81 M-17.15 M-15.31 M -15.31 M

News

Genprex stock jumps on Japan, Europe patent approvals

Genprex receives Japanese and European patents for cancer therapy

Genprex receives patent approval in Australia for cancer therapy

Genprex reports positive data for diabetes gene therapy in animal studies

Genprex reports potential compliance with Nasdaq equity listing rule

Genprex reports phase 1 data for lung cancer gene therapy

Genprex receives US patent for cancer therapy combination

Genprex to receive European patent for cancer gene therapy combination

Genprex stock tumbles after announcing $3.4 million registered offering

Genprex announces $3.4 million registered direct offering

Genprex stock soars after positive preclinical lung cancer treatment data

Genprex reports positive preclinical data for lung cancer gene therapy